‘When it comes to fighting against the Covid-19 pandemic, Singapore has been punching above its weight. Blood samples from three patients here were used to develop the experimental antibody cocktail used to treat US President Donald Trump after he tested positive for the coronavirus.
‘The National Centre for Infectious Diseases (NCID) had responded to a collaboration request from US biotechnology firm Regeneron - the company which developed that antibody cocktail - with no claim of intellectual property right over the treatment.’
Read here (Straits Times, Oct 10, 2020)
